Formation of an Ag-->Al Dative Bond Is Avoided in Reactions of an Alane/tris(phosphine) Ligand with Monovalent Silver

2021 ◽  
Author(s):  
Qingheng Lai ◽  
Nattamai Bhuvanesh ◽  
Jia Zhou ◽  
Oleg V Ozerov
Keyword(s):  
Phosphine Ligand ◽  
Site Reaction ◽  
Dative Bond

An alane/tris(phospine) ligand reacts with AgOTf by coordination of three phosphines to the Ag center and transfer of triflate to the tris(pyrrolyl) Al site. Reaction with Ag[HCB11Cl11] results in the...

Polarity of a dative bond Donor and acceptor electronegativities

2018 ◽  
Vol 15 (4e) ◽  
pp. 335
Author(s):  
Julio J. Andrade Gamboa
Keyword(s):  
Dative Bond ◽  
Donor And Acceptor

<span>La polaridad de un enlace dativo entre átomos idénticos no puede ser explicada con base en las electronegatividades usuales. Si suponemos que ambos átomos tienen la misma electronegatividad, las cargas atómicas serán (tomando como unidad el valor absoluto de la carga del electrón) las cargas formales; esto es: —1 para el átomo aceptor y +1 para el átomo dador. Esto implica una polaridad anormalmente alta para un enlace covalente.</span>

Polarity of a dative bond Donor and acceptor electronegativities

2018 ◽  
Vol 15 (4e) ◽  
pp. 335
Author(s):  
Julio J. Andrade Gamboa
Keyword(s):  
Dative Bond ◽  
Donor And Acceptor

<span>La polaridad de un enlace dativo entre átomos idénticos no puede ser explicada con base en las electronegatividades usuales. Si suponemos que ambos átomos tienen la misma electronegatividad, las cargas atómicas serán (tomando como unidad el valor absoluto de la carga del electrón) las cargas formales; esto es: —1 para el átomo aceptor y +1 para el átomo dador. Esto implica una polaridad anormalmente alta para un enlace covalente.</span>

Ruthenium-catalyzed synthesis of N-substituted lactams by acceptorless dehydrogenative coupling of diols with primary amines

2019 ◽  
Vol 55 (82) ◽  
pp. 12384-12387 ◽  
Author(s):  
Yanling Zheng ◽  
Xufeng Nie ◽  
Yang Long ◽  
Li Ji ◽  
Haiyan Fu ◽  
...  
Keyword(s):  
Phosphine Ligand ◽  
Primary Amines ◽  
Dehydrogenative Coupling ◽  
One Step

The first synthesis of N-substituted lactams via an acceptorless dehydrogenative coupling of diols with primary amines in one step was enabled by combining Ru3(CO)12 with a hybrid N-heterocyclic carbene–phosphine–phosphine ligand as the catalyst.

Homo- and heterobimetallic trihydride complexes stabilized by the tripodal phosphine ligand MeC(CH2PPh2)3: experimental and theoretical studies

1989 ◽  
Vol 28 (13) ◽  
pp. 2552-2560 ◽  
Author(s):  
Claudio Bianchini ◽  
Franco Laschi ◽  
Dante Masi ◽  
Carlo Mealli ◽  
Andrea Meli ◽  
...  
Keyword(s):  
Phosphine Ligand ◽  
Theoretical Studies ◽  
Experimental And Theoretical Studies

Beyond the Classical Coordination Chemistry: The First Case of a Triply Bridging Phosphine Ligand

2021 ◽  
Author(s):  
Alexander V. Artem'ev ◽  
Andrey Yu. Baranov ◽  
Elena A. Pritchina ◽  
Alexey S. Berezin ◽  
Nina P. Gritsan ◽  
...  
Keyword(s):  
Coordination Chemistry ◽  
Phosphine Ligand ◽  
First Case

scholarly journals Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series

2021 ◽  
pp. 224-231
Author(s):  
Richard T. Lee ◽  
Peiying Yang ◽  
Asrar Alahmadi ◽  
Jennifer McQuade ◽  
Eric Yuan ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Time ◽  
Injection Site Reaction ◽  
Case Series ◽  
Advanced Hepatocellular Carcinoma ◽  
Site Reaction ◽  
Advanced Hcc ◽  
Mistletoe Extract ◽  
Sorafenib Therapy ◽  
Mistletoe Extracts

Background: Hepatocellular carcinoma (HCC) is the fourth leading cause of death from cancer worldwide, and for advanced HCC the prognosis is poor. Preliminary studies indicate mistletoe extracts may have anticancer activity for HCC. Methods: A prospective observational case series of advanced HCC patients that chose to take a mistletoe extract called viscum fraxini-2 (VF-2) alone for treatment. Time on treatment, imaging, and laboratory values were collected for descriptive analyses. Results: A total of 12 patients with advanced HCC enrolled onto the protocol, and 10 patients had data available for evaluation. The majority were male (10/12) with a median age of 64 (SD 11). Most patients had received sorafenib therapy (9/12) and had varying Child-Pugh classes (A-4, B-6, C-2). Treatment with VF-2 ranged from 1 to 36 weeks with a mean of 12.3 weeks (SD 12). Six patients received 8 weeks of treatment, and 3 patients received 12 or more weeks of treatment. For patients that received at least 4 weeks of treatment, the average AFP value stabilized during the first 4 weeks of treatment. Two patients experienced an AFP decrease of >30%, approximately 37 and 40% decreases at the nadir. One patient had stable disease of 9 months. Major side effects were fever, fatigue, rash, and local injection site reaction of swelling, redness, and tenderness. Conclusion: This case series of advanced HCC indicates that mistletoe extract VF-2 may have potential biological activity against HCC for selected patients. Research is needed to identify the active compound and predictive markers of response.

Sign in / Sign up

Export Citation Format

Share Document